Profusa, Inc. (PFSA)
NASDAQ: PFSA · Real-Time Price · USD
2.120
-0.420 (-16.54%)
At close: Jul 10, 2026, 4:00 PM EDT
2.030
-0.090 (-4.25%)
After-hours: Jul 10, 2026, 7:58 PM EDT
Profusa Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
395.19K
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 100.00K | 55.00K | 122.22% |
| Dec 31, 2023 | 45.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 742.00K | -3.20M | -81.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nuwellis | 8.77M |
| Beyond Air | 7.68M |
| INVO Fertility | 7.22M |
| Tenon Medical | 4.60M |
| Biomerica | 4.33M |
| Intelligent Bio Solutions | 3.91M |
| ENvue Medical | 2.18M |
| Catheter Precision | 1.11M |
PFSA News
- 4 days ago - Profusa Inc trading halted, news pending - TheFly
- 8 days ago - Profusa announces 1-for-25 reverse stock split - TheFly
- 8 days ago - Profusa Announces 1-for-25 Reverse Stock Split - GlobeNewsWire
- 16 days ago - Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts - GlobeNewsWire
- 4 weeks ago - Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform - GlobeNewsWire
- 4 weeks ago - Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting - GlobeNewsWire
- 2 months ago - Profusa to transfer listing to Nasdaq - TheFly
- 2 months ago - Profusa Announces Listing Transfer to The Nasdaq Capital Market - GlobeNewsWire